← brief for 2026-09-24 · People & money

TARGET-EU: Dapagliflozin and major adverse cardiovascular events in type 2 diabetes

Article No results yet Not peer reviewed

Key takeaways

This entry shares the code list used in a case study. It is part of a larger project to use real-world data for drug rules. There are no new results in this specific file.

Who did this work

Tomas Lasys (Utrecht University) · Sima Mohammadi (University Medical Center Utrecht) · Daniala L. Weir · Patrick Cyriel Souverein (Utrecht University) · Elisa Martín‐Merino (Agencia Española de Medicamentos y Productos Sanitarios) · Belén Castillo‐Cano (Agencia Española de Medicamentos y Productos Sanitarios) · Judit Riera‐Arnau (Universitat Autònoma de Barcelona) · Carlos E. Durán · Cristina Rebordosa (RTI Health Solutions) · Joan Fortuny (RTI Health Solutions) · Alejandro Arana (RTI Health Solutions) · Taylor Aurelius (Drug Safety Research Unit)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-23
https://doi.org/10.5281/zenodo.21219627